有证据表明,在心力衰竭中存在阿尔多激素对抗作用
Rishi Sethi1, Pravesh Vishwakarma1, Akshyaya Pradhan1
1Department of Cardiology, King George's Medical University Uttar Pradesh, India.
Cardiac failure review
|November 26, 2024
概括
阿尔多激素对抗剂通过阻断有害的心血管效应,有效地控制心力衰竭. 矿物甲基皮质类受体对抗剂,如螺旋和埃普莱伦,改善了结果,目前正在对新药进行研究.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸- ангиотензин- алдостерон系统的激活是心力衰竭病理生理学的核心.
- 阿尔多,除了对脏的影响外,还影响心血管组织,促进不良重塑和事件.
研究的目的:
- 审查阿尔多激素对抗在心力衰竭管理中的作用.
- 总结矿物质皮质类受体对抗剂改善心血管结果的证据.
主要方法:
- 对临床试验数据的审查,包括RALES,EPHESUS,EMPHASIS-HF和TOPCAT.
- 在心血管疾病中分析阿尔多素的病理生理机制.
主要成果:
- 斯皮罗诺拉克和埃普莱伦显著降低了心力衰竭患者的心血管事件.
- 在TOPCAT试验中,在心力衰竭中保留喷射分数的小组中,建议获得益处.
- 新的非类固醇抗剂和阿尔多氨酸合成酶抑制剂正在研究中.
结论:
- 阿尔多激素对抗是心力衰竭的关键治疗策略.
- 矿物质皮质类受体对抗剂提供了经过验证的心血管益处.
- 目前正在进行的开发目标是改善心力衰竭治疗的阿尔多激素阻塞.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
Antihypertensive Drugs: Angiotensin II Receptor Blockers
590
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
590
Antihypertensive Drugs: Action of β1 Blockers
307
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
307
Antihypertensive Drugs: Direct Renin Inhibitors
493
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
493


